Evidence map›Paper›PMID 29281498›Full record

ArticleSLAS technology2018

Continuous and Quantitative Purification of T-Cell Subsets for Cell Therapy Manufacturing Using Magnetic Ratcheting Cytometry.

Coleman Murray, Edward Pao, Andrew Jann, Da Eun Park, Dino Di Carlo

Open access · bronzeAbstract read
In one paragraph

Article in SLAS technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Coleman Murray1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Edward Pao1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Andrew Jann1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Da Eun Park1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
Dino Di Carlo1 Department of Bioengineering, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USCalifornia NanoSystems Institute · USUCLA Jonsson Comprehensive Cancer Center

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Secretion Encoding for Multiparameter Functional Immune AssaysU24AI118667 · NIAID · GENERAL ELECTRIC GLOBAL RESEARCH CTR · PI PULEO, CHRISTOPHER M · 2015 to 2019
$1.9M
NCI NIH HHS P30 CA016042NIAID NIH HHS U24 AI118667
6 · The paper itself

Abstract

T-cell-based immunotherapies represent a growing medical paradigm that has the potential to revolutionize contemporary cancer treatments. However, manufacturing bottlenecks related to the enrichment of therapeutically optimal T-cell subpopulations from leukopak samples impede scale-up and scale-out efforts. This is mainly attributed to the challenges that current cell purification platforms face in balancing the quantitative sorting capacity needed to isolate specific T-cell subsets with the scalability to meet manufacturing throughputs. In this work, we report a continuous-flow, quantitative cell enrichment platform based on a technique known as ratcheting cytometry that can perform complex, multicomponent purification targeting various subpopulations of magnetically labeled T cells directly from apheresis or peripheral blood mononuclear cell (PBMC) samples. The integrated ratcheting cytometry instrument and cartridge demonstrated enrichment of T cells directly from concentrated apheresis samples with a 97% purity and an 85% recovery of magnetically tagged cells. Magnetic sorting of different T-cell subpopulations was also accomplished on chip by multiplexing cell surface targets onto particles with differing magnetic strengths. We believe that ratcheting cytometry's quantitative capacity and throughput scalability represents an excellent technology candidate to alleviate cell therapy manufacturing bottlenecks.

Indexed as

Cell- and Tissue-Based TherapyMagnetic PhenomenaAutomationCD3 ComplexCell SeparationFlow CytometryHL-60 CellsHumansJurkat CellsT-Lymphocyte SubsetsCD3 Complexcell therapy manufacturingimmunotherapyratcheting cytometry

Identifiers

PMID29281498
PMCPMC6092733
OpenAlexW2777825888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.